Browsing Tag
Boehringer Ingelheim Pharmaceuticals
1 post
Insilico Medicine’s AI drug enters Phase III dosing. Can rentosertib clear the real test?
Insilico Medicine has dosed the first patient in its 320-patient Phase III GENESIS-IPF-3 study, moving rentosertib from an intriguing AI-drug discovery milestone into a year-long test of whether its earlier lung-function signal can survive pivotal clinical scrutiny.